[SARS-CoV-2 vaccines and reaction of the immune system. Can the epidemic spread of the virus be prevented by vaccination?]

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Schmidt J; Blessing F; Gürtler L
  • Source:
    Deutsche medizinische Wochenschrift (1946) [Dtsch Med Wochenschr] 2021 Aug; Vol. 146 (16), pp. 1085-1090. Date of Electronic Publication: 2021 Aug 20.
  • Publication Type:
    Journal Article
  • Language:
    German
  • Additional Information
    • Transliterated Title:
      SARS-CoV-2-Impfstoffe und Reaktion des Immunsystems. Kann die epidemische Ausbreitung des Virus durch Impfung verhindert werden?
    • Source:
      Publisher: G. Thieme Country of Publication: Germany NLM ID: 0006723 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1439-4413 (Electronic) Linking ISSN: 00120472 NLM ISO Abbreviation: Dtsch Med Wochenschr Subsets: MEDLINE
    • Publication Information:
      Original Publication: Stuttgart [etc.] : G. Thieme, 1946-
    • Subject Terms:
      COVID-19/*prevention & control ; COVID-19 Vaccines/*immunology ; Immune System/*physiology ; SARS-CoV-2/*immunology ; Vaccination/*standards; COVID-19/epidemiology ; COVID-19/physiopathology ; Humans ; Immune System/immunology ; Immunity, Cellular ; Immunity, Humoral ; Time Factors
    • Abstract:
      Since the end of 2019 a new coronavirus, SARS-CoV-2, first identified in Wuhan, China, is spreading around the world partially associated with a high death toll. Besides hygienic measurements to reduce the spread of the virus vaccines have been confected, partially based on the experiences with Ebola virus vaccine, based on recombinant human or chimpanzee adenovirus carrying the spike protein and its ACE2 receptor binding domain (RBD). Further vaccines are constructed by spike protein coding mRNA incorporated in lipid nano vesicles that after entry in human cells produce spike protein. Both vaccine types induce a strong immune response that lasts for months possibly for T-cell immunity a few years. Due to mutations in the coronavirus genome in several parts of the world variants selected, that were partially more pathogenic and partially easier transmissible - variants of concern (VOC). Until now vaccinees are protected against the VOC, even when protection might be reduced compared to the Wuhan wild virus.An open field is still how long the vaccine induced immunity will be sufficient to prevent infection and/or disease; and how long the time period will last until revaccination will be required for life saving protection, whether a third vaccination is needed, and whether revaccination with an adenovirus-based vaccine will be tolerated.
      Competing Interests: Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
      (Thieme. All rights reserved.)
    • Accession Number:
      0 (COVID-19 Vaccines)
    • Publication Date:
      Date Created: 20210820 Date Completed: 20210902 Latest Revision: 20210902
    • Publication Date:
      20231215
    • Accession Number:
      10.1055/a-1550-0001
    • Accession Number:
      34416777